CHUNLI MEDICAL (01858) rose more than 4%. At the time of writing, the stock was up 1.85%, trading at HKD 14.88, with a turnover of HKD 5.3193 million. On January 29, CHUNLI MEDICAL released its 2025 performance forecast. Preliminary calculations by the company's finance department indicate that the net profit attributable to owners of the parent company for the full year 2025 is expected to be between RMB 245 million and RMB 288 million. This represents an increase of RMB 120 million to RMB 163 million compared to the same period last year, a year-on-year rise of 96.01% to 130.41%. The net profit attributable to owners of the parent company after deducting non-recurring gains and losses is projected to be between RMB 230 million and RMB 270 million. This is an increase of RMB 135 million to RMB 175 million compared to the prior year period, a significant year-on-year surge of 142.80% to 185.11%. The announcement stated that for the 2025 fiscal year, both the net profit attributable to shareholders and the net profit after excluding non-recurring items achieved substantial growth compared to the same period last year. During the reporting period, the growth potential of the company's various product lines was gradually unleashed following their inclusion in the national volume-based procurement program. Concurrently, the company persistently implemented its international development strategy and steadily advanced its global business layout, driving sustained, stable, and healthy growth in operating revenue through a dual focus on domestic and international markets. Furthermore, the company concentrated on enhancing its management and operational standards and optimizing resource allocation. These measures further improved operational efficiency, strengthened overall profitability, and provided robust support for the strong earnings growth.